Baxter Awaits Further FDA Contact Regarding CAPA, MDR Deficiencies
This article was originally published in The Gray Sheet
Executive Summary
Baxter Healthcare's response to Form 483 inspection observations insufficiently addresses FDA concerns about corrective and preventive actions (CAPA), the agency says in a warning letter released April 19